mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.002 |
mRNA |
MK 1775 |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.002 |
mRNA |
SB-225002 |
CTRPv2 |
pan-cancer |
AAC |
-0.096 |
0.002 |
mRNA |
S-Trityl-L-cysteine |
GDSC1000 |
pan-cancer |
AAC |
-0.15 |
0.002 |
mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.003 |
mRNA |
Docetaxel |
gCSI |
pan-cancer |
AAC |
-0.16 |
0.003 |
mRNA |
tivantinib |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.003 |
mRNA |
BMS-345541 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.003 |
mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.098 |
0.004 |
mRNA |
BRD-K80183349 |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.004 |